Eli Lilly increases production capacity

Note: This section contains information in English only.
Source: Dukascopy Bank SA


The US pharmaceutical firm Eli Lilly has announced a stunning financial quarter, as the firm has managed to increase production of weight loss drugs. The stock price of the company was set to start Thursday's trading with a gap up of nearly 9.00%.

The company has been experiencing major demand for its weight loss drugs. However, it had struggled to meet the demand, as just like its competitors, it did not have the capacity to produce and distribute the highly sought after drugs. On Wednesday, the main competitor Novo Nordisk announced that it has failed to meet quarterly expectations. Markets expected the same from Eli Lilly to be announced today.

Quite the opposite was revealed on Thursday. In fact, the firm has managed to breach the $1 billion sales benchmark for its weight loss drug Zepbound. Moreover, the company has increased its 2024 profit forecast by $3 billion.

Actual Topics

Subscribe to "Fundamental Analysis" feed

Subscribe
Aby dowiedzieć się więcej o handlu Forex/CFD na platformie Dukascopy Banku, rynku SWFX oraz innych rzeczy związanych z handlem,
zadzwoń do nas lub poproś o oddzwonienie.
For further information regarding potential cooperation,
please call us or make callback request.
Aby dowiedzieć się więcej o Opcjach Binarnych w Banku Dukascopy / platformach handlowych Forex, SWFX, oraz innych,
zadzwoń do nas lub pozostaw prośbę o oddzwonienie.
Aby dowiedzieć się więcej o handlu Forex/CFD na platformie Dukascopy Banku, rynku SWFX oraz innych rzeczy związanych z handlem,
zadzwoń do nas lub poproś o oddzwonienie.
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Business Introducer and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.